View ValuationStemtech 将来の成長Future 基準チェック /06現在、 Stemtechの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長34.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 01Stemtech Corporation announced delayed annual 10-K filingOn 03/31/2026, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 07Stemtech Corporation Appoints Dr. Lizette Leos, MD as Chief Scientific OfficerStemtech Corporation appointed Dr. Lizette Leos, MD to Chief Scientific Officer. Dr. Leos has been with Stemtech since 2017 and has significantly contributed to the science, creation and development, including education of stemceuticals all-natural, plant-based, non-GMO nutritional supplements designed to support the body's own regenerative processes. Promoting her to the role of Chief Scientific Officer recognizes both her longstanding impact and leadership in the development of new evidence-driven innovations. Her scientific knowledge of products, ability to translate complex biology into practical education, and commitment to Stemtech's non-chemical approaches to cellular health have been instrumental to Stemtech's growth, with focus on anti-aging and longevity. As Chief Scientific Officer, Dr. Leos will lead Stemtech Corporation's global scientific validation, education and regulatory alignment for Stemtech's recently announced joint ventures in Stemtech HealthSciences India Pvt Ltd. and the GCC (Gulf Cooperation Council countries of the United Arab Emirates, Bahrain, Saudi Arabia, Qatar, Kuwait and Oman). In addition, Dr. Leos will also support Stemtech Asia (Hong Kong) for business in the Peoples Republic of China. Dr. Leos is a medical doctor based in Guadalajara, Mexico, and has worked with Stemtech since 2017. She holds a Master's Degree in Aesthetic and Anti-Aging Medicine from the Instituto Mexicano de Medicina Antienvejecimiento y Esttica (IMMAE) (2023), postgraduate training in Molecular Nutrition and Smart Food Design from Tecnológico de Monterrey, Campus Guadalajara (2018), and earned her Medical Degree from Universidad Guadalajara Lamar, with her professional title issued by the Universidad de Guadalajara (2007). With over 10 years of experience in regenerative medicine, nutrigenomics, cellular health, and aesthetic medicine, Dr. Leos has served on the Stemtech Life Sciences Advisory Board, where she has designed global educational programs, scientific symposiums, and evidence-based clinical and educational protocols. She brings deep expertise in scientific and medical communication, clinical protocol development, and cross-functional collaboration across scientific, regulatory, and commercial teams. Fluent in English and Spanish, she contributes significant cross-cultural leadership to Stemtech's international operations.お知らせ • Nov 15Stemtech Corporation announced delayed 10-Q filingOn 11/14/2025, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15Stemtech Corporation announced delayed 10-Q filingOn 08/14/2025, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16+ 1 more updateStemtech Corporation announced delayed amended 10-Q filingOn 05/15/2025, Stemtech Corporation announced that they will be unable to file their amended 10-Q by the deadline required by the SEC.お知らせ • Apr 15Stemtech Corporation Announces CFO ChangesOn April 11, 2025, James Cardwell resigned his position as CFO of Stemtech Corporation. At the same time the Board appointed Shrilakshmi Vadlapatla as CFO. Ms. Vadlapatla, 40, is a seasoned boutique accountant with years of experience in audit compliance, SEC reporting, internal controls, Sarbanes-Oxley compliance and strategic financial management. With a strong background in GAAP and IFRS principles, earnings analysis, and external audits, she provides expertise in risk assessment, Sarbanes-Oxley compliance, and the development of robust financial policies and procedures. Ms. Vadlapatla holds a Bachelor of Commerce in Accounting from Osmania University, (India), 2005.お知らせ • Apr 01Stemtech Corporation announced delayed annual 10-K filingOn 03/31/2025, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Dec 02Stemtech Corporation signed a letter of intent to acquire Eevia Health Oyj (NGM:EEVIA) in a reverse merger transaction.Stemtech Corporation signed a letter of intent to acquire Eevia Health Oyj (NGM:EEVIA) in a reverse merger transaction on November 10, 2024. The proposal suggests that Eevia buy the Stemtech's assets (“Stemtech Assets”) and issue new shares to the Stemtech, providing that Stemtech will own c. 85% of the new outstanding shares after such a transaction. Stemtech's valuation would be approximately $40 million, and the remaining 15% of the shares would value Eevia at approximately $6-7 million. The final valuation, number of shares to be issued, and issue price are subject to negotiation and the due diligence process of both companies.お知らせ • Nov 20Stemtech Corporation (OTCPK:STEK) entered into an agreement in principle to acquire SEACRET Direct, LLC.Stemtech Corporation (OTCPK:STEK) entered into an agreement in principle to acquire SEACRET Direct, LLC on November 20, 2024. The proposed merger is expected to be for all stock consideration and is subject to conditions to closing, including required board and shareholder approvals, the finalization of definitive agreements, the audit of VIÁGO financial statements and other customary conditions. Stemtech and VIÁGO expect to finalize the definitive agreements for the merger soon.お知らせ • Nov 15Stemtech Corporation announced delayed 10-Q filingOn 11/14/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 23Stemtech Corporation Announces the Launch of StemPetsStemtech Corporation announced an exciting new product line into the pet health care industry with the launch of StemPets™?. This revolutionary product is designed to provide substantial health benefits to dogs, cats, and other beloved pets, tapping into the $303 billion pet health care market. Recognizing the profound love humans hold for their pets and the significant expenses they incur to keep them healthy, Stemtech has developed StemPets. This natural stemceutical product promises to offer amazing health benefits to pets as human products have provided for nearly two decades. Stemtech has negotiated an exclusive distribution agreement for StemPets, ensuring that this novel product will be available through established channels. Over the past year, company has tested StemPets with a variety of pet owners, receiving overwhelmingly positive feedback regarding its natural taste and health benefits. This expansion into the pet health care industry also presents a significant opportunity for younger distributors of products, including Gen X individuals under 40 who may not yet prioritize human stem cell health but are enthusiastic about superior health products for their pets. Stemtech's dedication to scientific innovation and health continues with the introduction of StemPets, marking a new chapter in mission to improve lives, both human and animal.お知らせ • Aug 15Stemtech Corporation announced delayed 10-Q filingOn 08/14/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Stemtech Corporation announced delayed 10-Q filingOn 05/15/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Mar 30Stemtech Corporation announced delayed annual 10-K filingOn 03/29/2024, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15Stemtech Corporation announced delayed 10-Q filingOn 11/14/2023, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 11Stemtech Corporation Appoints Margie and Mike Mares to Field Advisory BoardStemtech Corporation announced the appointment of Margie and Mike Mares of Stemtech Mexico to Stemtech's Field Advisory Board (FAB). Margie has a degree in Communications and has also worked in the cosmetic industry as a senior executive in the areas of sales, marketing and public relations. Mike has earned a Bachelor of Business Administration and Marketing from UP and a Professional Photographer from NYIP. He has experience in marketing, e-commerce, Community Management and growth of markets and social networks, management and the creation of bots, logistics and finance.お知らせ • Dec 07Stemtech Corporation Announces Introduction of Cellectone Rapid Renew Stem Cell Peptide Night CreamStemtech Corporation (Stemtech) announced the introduction of their new CellectOne™ innovative and cutting-edge Skincare line, with the first product being the Rapid Renew Stem Cell Peptide Night Cream.お知らせ • Sep 20Stemtech Corporation Announces Creation of New Stem Cell Skincare ProductsStemtech Corporation announced creation of new stem cell skincare products.お知らせ • Sep 07Stemtech Corporation Announces Professor Dr. Bankole Johnson Joins Their Life Sciences Advisory BoardStemtech Corporation announced that Professor Dr. Bankole Johnson joins the Stemtech Corporation Life Sciences Advisory Board (LSAB). Forbes Magazine articulated that “Dr. Johnson was a fully-practicing MD by the age of 22, when he became an intensive care doctor. After that, and after completing the necessary schooling, he became an anesthesiologist, and then a psychiatrist. He further pursued higher education with the completion of two more doctorates in addition to his MD, and a Masters Degree in neurological disorders and computational mathematics. While practicing medicine and making discoveries in the areas of psychopharmacology in the treatment of addiction, he rose in academia to become the Alumni Professor and Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, followed by a similar role at the University of Maryland where he was Chairman of Psychiatry and Professor of pharmacology, medicine, psychiatry, anatomy, neurobiology, and neurology.” Professor Dr. Bankole Johnson gained national attention for his appearance in the Home Box Office (HBO) 2007 documentary Addiction, which won the Governor’s Award (a special Emmy Award) from the Academy of Television Arts and Sciences. This being the highest award presented by the Academy. He also appeared on the esteemed 2009 CNN special, anchored by Chief Medical Correspondent Dr. Sanjay Gupta, called Addiction: Life on the Edge. Furthermore, Professor Dr. Bankole Johnson is a regular medical correspondent for major network channels in the USA, especially during the COVID-19 pandemic. Presently, Dr. Johnson is the Founder, Executive Chairman, and CEO of Casa Privée, based in Miami, and the Founder and Chief Medical Officer of Adial Pharmaceuticals Inc., a NASDAQ listed company. Professor Dr. Johnson also functions as a Professor of Biomedical Sciences at Larkin University in Miami.お知らせ • Aug 30Stemtech Corporation (OTCPK:STEK) entered into a letter of intent to acquire Life Factor Research.Stemtech Corporation (OTCPK:STEK) entered into a letter of intent to acquire Life Factor Research on August 29, 2022.お知らせ • Aug 24Stemtech Corporation Announces Orastem Trademark Registration in Mexico and Introduces New Travel SizeStemtech Corporation announced that OraStem®, Stemtech’s all-natural toothpaste, has been trademarked registered in Mexico. OraStem is composed of fourteen natural, non-GMO, and organic ingredients: powerful antioxidants, botanicals, herbal extracts, CoQ10, vitamins, and natural flavors. Their efficacy and safety for oral health have been supported by dozens of studies published in peer-reviewed journals. Stemtech will also be introducing a new sample /travel size of OraStem soon. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and international markets. Its patented formulas help the release, circulation and migration of the body’s adult stem cells from the bone marrow. Also offered is the OraStem and D-Fuze, an Electro Magnetic Field blocker. Its nutraceutical products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplemental Health and Education Act (DSHEA). Stemtech has a history of innovation and was the first to market in the category of stem cell nutrition and was recognized four separate times by Inc. 5000 Fastest-Growing Companies list. Stemtech’s primary marketing and distribution channel is through a direct sales structure, which offers supplemental and residual income-earning potential to IBPs. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Stemtech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:STEK - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20254-3-1-1N/A6/30/20254-3-2-2N/A3/31/20255-4-2-2N/A12/31/20245-4-1-1N/A9/30/20245-5-1-1N/A6/30/20245-500N/A3/31/20245-500N/A12/31/20235-5-2-2N/A9/30/20235-4-1-1N/A6/30/2023414-1-1N/A3/31/20235-10-2-2N/A12/31/20225-9-1-1N/A9/30/20225-9-3-3N/A6/30/20225-32-2-2N/A3/31/20224-7-2-2N/A12/31/20214-7-2-2N/A9/30/20214-7-1-1N/A6/30/20214-200N/A3/31/20214-100N/A12/31/20204-100N/A12/31/20197-3-1-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: STEKの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: STEKの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: STEKの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: STEKの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: STEKの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: STEKの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 10:09終値2026/05/11 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Stemtech Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 01Stemtech Corporation announced delayed annual 10-K filingOn 03/31/2026, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 07Stemtech Corporation Appoints Dr. Lizette Leos, MD as Chief Scientific OfficerStemtech Corporation appointed Dr. Lizette Leos, MD to Chief Scientific Officer. Dr. Leos has been with Stemtech since 2017 and has significantly contributed to the science, creation and development, including education of stemceuticals all-natural, plant-based, non-GMO nutritional supplements designed to support the body's own regenerative processes. Promoting her to the role of Chief Scientific Officer recognizes both her longstanding impact and leadership in the development of new evidence-driven innovations. Her scientific knowledge of products, ability to translate complex biology into practical education, and commitment to Stemtech's non-chemical approaches to cellular health have been instrumental to Stemtech's growth, with focus on anti-aging and longevity. As Chief Scientific Officer, Dr. Leos will lead Stemtech Corporation's global scientific validation, education and regulatory alignment for Stemtech's recently announced joint ventures in Stemtech HealthSciences India Pvt Ltd. and the GCC (Gulf Cooperation Council countries of the United Arab Emirates, Bahrain, Saudi Arabia, Qatar, Kuwait and Oman). In addition, Dr. Leos will also support Stemtech Asia (Hong Kong) for business in the Peoples Republic of China. Dr. Leos is a medical doctor based in Guadalajara, Mexico, and has worked with Stemtech since 2017. She holds a Master's Degree in Aesthetic and Anti-Aging Medicine from the Instituto Mexicano de Medicina Antienvejecimiento y Esttica (IMMAE) (2023), postgraduate training in Molecular Nutrition and Smart Food Design from Tecnológico de Monterrey, Campus Guadalajara (2018), and earned her Medical Degree from Universidad Guadalajara Lamar, with her professional title issued by the Universidad de Guadalajara (2007). With over 10 years of experience in regenerative medicine, nutrigenomics, cellular health, and aesthetic medicine, Dr. Leos has served on the Stemtech Life Sciences Advisory Board, where she has designed global educational programs, scientific symposiums, and evidence-based clinical and educational protocols. She brings deep expertise in scientific and medical communication, clinical protocol development, and cross-functional collaboration across scientific, regulatory, and commercial teams. Fluent in English and Spanish, she contributes significant cross-cultural leadership to Stemtech's international operations.
お知らせ • Nov 15Stemtech Corporation announced delayed 10-Q filingOn 11/14/2025, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15Stemtech Corporation announced delayed 10-Q filingOn 08/14/2025, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16+ 1 more updateStemtech Corporation announced delayed amended 10-Q filingOn 05/15/2025, Stemtech Corporation announced that they will be unable to file their amended 10-Q by the deadline required by the SEC.
お知らせ • Apr 15Stemtech Corporation Announces CFO ChangesOn April 11, 2025, James Cardwell resigned his position as CFO of Stemtech Corporation. At the same time the Board appointed Shrilakshmi Vadlapatla as CFO. Ms. Vadlapatla, 40, is a seasoned boutique accountant with years of experience in audit compliance, SEC reporting, internal controls, Sarbanes-Oxley compliance and strategic financial management. With a strong background in GAAP and IFRS principles, earnings analysis, and external audits, she provides expertise in risk assessment, Sarbanes-Oxley compliance, and the development of robust financial policies and procedures. Ms. Vadlapatla holds a Bachelor of Commerce in Accounting from Osmania University, (India), 2005.
お知らせ • Apr 01Stemtech Corporation announced delayed annual 10-K filingOn 03/31/2025, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Dec 02Stemtech Corporation signed a letter of intent to acquire Eevia Health Oyj (NGM:EEVIA) in a reverse merger transaction.Stemtech Corporation signed a letter of intent to acquire Eevia Health Oyj (NGM:EEVIA) in a reverse merger transaction on November 10, 2024. The proposal suggests that Eevia buy the Stemtech's assets (“Stemtech Assets”) and issue new shares to the Stemtech, providing that Stemtech will own c. 85% of the new outstanding shares after such a transaction. Stemtech's valuation would be approximately $40 million, and the remaining 15% of the shares would value Eevia at approximately $6-7 million. The final valuation, number of shares to be issued, and issue price are subject to negotiation and the due diligence process of both companies.
お知らせ • Nov 20Stemtech Corporation (OTCPK:STEK) entered into an agreement in principle to acquire SEACRET Direct, LLC.Stemtech Corporation (OTCPK:STEK) entered into an agreement in principle to acquire SEACRET Direct, LLC on November 20, 2024. The proposed merger is expected to be for all stock consideration and is subject to conditions to closing, including required board and shareholder approvals, the finalization of definitive agreements, the audit of VIÁGO financial statements and other customary conditions. Stemtech and VIÁGO expect to finalize the definitive agreements for the merger soon.
お知らせ • Nov 15Stemtech Corporation announced delayed 10-Q filingOn 11/14/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 23Stemtech Corporation Announces the Launch of StemPetsStemtech Corporation announced an exciting new product line into the pet health care industry with the launch of StemPets™?. This revolutionary product is designed to provide substantial health benefits to dogs, cats, and other beloved pets, tapping into the $303 billion pet health care market. Recognizing the profound love humans hold for their pets and the significant expenses they incur to keep them healthy, Stemtech has developed StemPets. This natural stemceutical product promises to offer amazing health benefits to pets as human products have provided for nearly two decades. Stemtech has negotiated an exclusive distribution agreement for StemPets, ensuring that this novel product will be available through established channels. Over the past year, company has tested StemPets with a variety of pet owners, receiving overwhelmingly positive feedback regarding its natural taste and health benefits. This expansion into the pet health care industry also presents a significant opportunity for younger distributors of products, including Gen X individuals under 40 who may not yet prioritize human stem cell health but are enthusiastic about superior health products for their pets. Stemtech's dedication to scientific innovation and health continues with the introduction of StemPets, marking a new chapter in mission to improve lives, both human and animal.
お知らせ • Aug 15Stemtech Corporation announced delayed 10-Q filingOn 08/14/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Stemtech Corporation announced delayed 10-Q filingOn 05/15/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Mar 30Stemtech Corporation announced delayed annual 10-K filingOn 03/29/2024, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15Stemtech Corporation announced delayed 10-Q filingOn 11/14/2023, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 11Stemtech Corporation Appoints Margie and Mike Mares to Field Advisory BoardStemtech Corporation announced the appointment of Margie and Mike Mares of Stemtech Mexico to Stemtech's Field Advisory Board (FAB). Margie has a degree in Communications and has also worked in the cosmetic industry as a senior executive in the areas of sales, marketing and public relations. Mike has earned a Bachelor of Business Administration and Marketing from UP and a Professional Photographer from NYIP. He has experience in marketing, e-commerce, Community Management and growth of markets and social networks, management and the creation of bots, logistics and finance.
お知らせ • Dec 07Stemtech Corporation Announces Introduction of Cellectone Rapid Renew Stem Cell Peptide Night CreamStemtech Corporation (Stemtech) announced the introduction of their new CellectOne™ innovative and cutting-edge Skincare line, with the first product being the Rapid Renew Stem Cell Peptide Night Cream.
お知らせ • Sep 20Stemtech Corporation Announces Creation of New Stem Cell Skincare ProductsStemtech Corporation announced creation of new stem cell skincare products.
お知らせ • Sep 07Stemtech Corporation Announces Professor Dr. Bankole Johnson Joins Their Life Sciences Advisory BoardStemtech Corporation announced that Professor Dr. Bankole Johnson joins the Stemtech Corporation Life Sciences Advisory Board (LSAB). Forbes Magazine articulated that “Dr. Johnson was a fully-practicing MD by the age of 22, when he became an intensive care doctor. After that, and after completing the necessary schooling, he became an anesthesiologist, and then a psychiatrist. He further pursued higher education with the completion of two more doctorates in addition to his MD, and a Masters Degree in neurological disorders and computational mathematics. While practicing medicine and making discoveries in the areas of psychopharmacology in the treatment of addiction, he rose in academia to become the Alumni Professor and Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, followed by a similar role at the University of Maryland where he was Chairman of Psychiatry and Professor of pharmacology, medicine, psychiatry, anatomy, neurobiology, and neurology.” Professor Dr. Bankole Johnson gained national attention for his appearance in the Home Box Office (HBO) 2007 documentary Addiction, which won the Governor’s Award (a special Emmy Award) from the Academy of Television Arts and Sciences. This being the highest award presented by the Academy. He also appeared on the esteemed 2009 CNN special, anchored by Chief Medical Correspondent Dr. Sanjay Gupta, called Addiction: Life on the Edge. Furthermore, Professor Dr. Bankole Johnson is a regular medical correspondent for major network channels in the USA, especially during the COVID-19 pandemic. Presently, Dr. Johnson is the Founder, Executive Chairman, and CEO of Casa Privée, based in Miami, and the Founder and Chief Medical Officer of Adial Pharmaceuticals Inc., a NASDAQ listed company. Professor Dr. Johnson also functions as a Professor of Biomedical Sciences at Larkin University in Miami.
お知らせ • Aug 30Stemtech Corporation (OTCPK:STEK) entered into a letter of intent to acquire Life Factor Research.Stemtech Corporation (OTCPK:STEK) entered into a letter of intent to acquire Life Factor Research on August 29, 2022.
お知らせ • Aug 24Stemtech Corporation Announces Orastem Trademark Registration in Mexico and Introduces New Travel SizeStemtech Corporation announced that OraStem®, Stemtech’s all-natural toothpaste, has been trademarked registered in Mexico. OraStem is composed of fourteen natural, non-GMO, and organic ingredients: powerful antioxidants, botanicals, herbal extracts, CoQ10, vitamins, and natural flavors. Their efficacy and safety for oral health have been supported by dozens of studies published in peer-reviewed journals. Stemtech will also be introducing a new sample /travel size of OraStem soon. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and international markets. Its patented formulas help the release, circulation and migration of the body’s adult stem cells from the bone marrow. Also offered is the OraStem and D-Fuze, an Electro Magnetic Field blocker. Its nutraceutical products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplemental Health and Education Act (DSHEA). Stemtech has a history of innovation and was the first to market in the category of stem cell nutrition and was recognized four separate times by Inc. 5000 Fastest-Growing Companies list. Stemtech’s primary marketing and distribution channel is through a direct sales structure, which offers supplemental and residual income-earning potential to IBPs.